Eventide Asset Management’s Wave Life Sciences WVE Stock Holding History

Eventide Asset Management’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-500,000	Closed	-$8.5M	–	311
2025 Q4	$8.5M	Buy	+500,000	New	+$5.08M	0.13%	150
2019 Q2	–	Sell	-170,400	Closed	-$6.62M	–	131
2019 Q1	$6.62M	Hold	170,400	–	–	0.23%	83
2018 Q4	$7.16M	Hold	170,400	–	–	0.32%	79
2018 Q3	$8.52M	Sell	170,400 -156,000	-48%	-$7.04M	0.31%	82
2018 Q2	$12.5M	Sell	326,400 -51,600	-14%	-$2.22M	0.52%	67
2018 Q1	$15.2M	Sell	378,000 -55,500	-13%	-$2.33M	0.71%	53
2017 Q4	$15.2M	Hold	433,500	–	–	0.79%	47
2017 Q3	$9.43M	Hold	433,500	–	–	0.53%	61
2017 Q2	$8.06M	Hold	433,500	–	–	0.5%	55
2017 Q1	$11.9M	Buy	433,500 +49,870	+13%	+$1.39M	0.79%	45
2016 Q4	$10M	Buy	383,630 +3,630	+1%	+$118K	0.65%	50
2016 Q3	$12.3M	Hold	380,000	–	–	0.75%	47
2016 Q2	$7.86M	Buy	+380,000	New	+$5.92M	0.48%	58

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

GSK plc London $602M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Eventide Asset Management's WVE Position: Q1 2026 in Review

Eventide Asset Management sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 500,000 shares — an estimated $8.5M sold.

Eventide Asset Management first reported a position in WVE in Q2 2016 and held it in 13 quarters. The position peaked at $15.2M in Q4 2017. 232 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

Eventide Asset Management reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
Eventide Asset Management sold 500,000 Wave Life Sciences shares in Q1 2026, an estimated $8.5M.
Eventide Asset Management first reported a position in Wave Life Sciences in Q2 2016 and held it in 13 quarters.
Eventide Asset Management's Wave Life Sciences position peaked at $15.2M in Q4 2017.
232 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.